SICHUAN-DIGITAL-PANDA
3.11.2020 18:02:11 CET | Business Wire | Press release
With the theme of "Panda World, World Panda--For Nature As It Is", the first digital International Panda Festival is hosted by Sichuan Forestry and Grassland Administration (Giant Panda National Park Sichuan Administration), Information Office of Sichuan Provincial People's Government, Sichuan Foreign Affairs Office, Sichuan Internet Information Office, International Union for Conservation of Nature (IUCN) China Representative Office, organized by Sichuan Digital Panda Technology Development Co., Ltd., co-organized by Sichuan Provincial People's Association for Friendship with Foreign Countries, Chengdu Research Base of Giant Panda Breeding and Sichuan Giant Panda Protection Foundation.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20201103005025/en/
Giant pandas are the "messenger of peace" in China's opening to the outside world. Sichuan ranks first in the area of giant panda habitat, the number of wild giant panda population and captive giant pandas in China.
Sichuan, as one of the pilot areas of the Giant Panda National Park, covers an area of 20,177 square kilometers, accounting for 74.36%. There are 1,227 giant pandas in the wild, accounting for 75.23%.
The opening ceremony launches a “space-air-ground-man” integrated digital platform. Locals will be able to learn about the life of Sichuan-based giant pandas living in foreign countries. Meanwhile, it releases books such as the Gift of Nature - Discovering Sichuan as It Is , Landscape of Bamboo forests in Sichuan , Secret Sichuan - the 88 Most Beautiful Forest and Grass Landscapes to Go . It also releases the top six lists of “the Most Beautiful Bamboo Landscape” in Chengdu-Chongqing Economic Circle, as well as the Guidelines on Promoting the Development of Natural Education by eight departments including Sichuan Provincial Forestry and Grassland Administration, Sichuan Provincial Development and Reform Commission, Education Department of Sichuan Province, etc. Besides, Forest and Grassland Fire Research Institute, Sichuan Academy of Forestry Sciences are inaugurated.
Six forums and three conferences systematically present successful experiences in building high-quality forest and grassland fire barriers. Exhibitions such as the Nature Reserve Photo Exhibition, the Giant Panda Cultural and Creative Exhibition, and the Giant Panda International Art Exhibition make you appreciate the unique charm.
The digital International Panda Festival will strive to develop into a branded network exchange platform with distinctive themes at both national and international levels, making itself the only global flagship platform with western characteristics in China.
View source version on businesswire.com: https://www.businesswire.com/news/home/20201103005025/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Barilla Opens Global Call for Startups Through Good Food Makers 202625.5.2026 11:47:00 CEST | Press release
The program has involved over 1,100 startups across 50+ countries, delivering 26 pilot projects. Barilla Group has opened applications for the 2026 edition of Good Food Makers, its global open innovation program designed to co-develop and test new innovative solutions with startups and innovators inside real industrial environments. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521973445/en/ Since its launch in 2019, the program has involved more than 1,100 startups from over 50 countries, leading to 26 pilot projects, with over 20 projects currently active thanks to the solutions developed by the program’s alumni. This highlights the program’s role as a concrete platform for industrial scalable innovation. The 2026 edition comes at a pivotal moment for the company, following the launch of BITE (Barilla Innovation & Technology Experience), the new innovation center dedicated to developing the next generation of food prod
JEOL: Sales Launch of the Laser SEM System “LazEdge”25.5.2026 10:16:00 CEST | Press release
JEOL Ltd. (President & CEO: Izumi Oi) has developed the “LazEdge”, an SEM system equipped with a laser processing system, and begins sales on May 25, 2026. Cross-section preparation instruments such as the focused ion beam system (FIB system), are widely used in science and technology fields across research institutes, universities, and industries. In recent years, demand is increasing for a system that can process large-areas at a high speed, while achieving high-quality of the processed surface. “LazEdge” is an instrument integrating JEOL’s SEM with the laser technology proprietary of Hamamatsu Photonics K.K., and enables laser processing inside the specimen chamber of the electron microscope. This system enables high-quality cross-section specimens produced through high-speed, large-area processing to be transferred seamlessly to subsequent analyses, such as SEM observation, elemental analysis, and crystal orientation analysis, without exposure to the external environment. As a resu
TFG-001, A Novel 3D Neural Microtissue Cell Therapy, Demonstrates Superior Functionality and Reinnervation for Parkinson’s Disease25.5.2026 08:00:00 CEST | Press release
TreeFrog Therapeutics, a regenerative medicine biotech company developing next-generation cell therapies, today announced that it will present new preclinical data on TFG-001 at the 7th World Parkinson’s Conference. TFG-001, a 3D neural microtissue cell therapy, demonstrated rapid dopamine release and extensive graft-derived reinnervation across multiple advanced translational Parkinson’s disease models—supporting its potential as a best-in-class candidate. The critical need for reinnervation in Parkinson's disease In Parkinson's disease, an estimated 60–80% of dopaminergic neurons are already lost before motor symptoms even appear. The nigrostriatal pathway degenerates, destroying the essential wiring that connects dopamine-producing neurons to movement control. While chemical dopamine replacements (like levodopa) can manage symptoms, they cannot restore the spatial precision, feedback loops, or dynamic regulation of a healthy brain network. To achieve true functional restoration, it
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom